The company Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) hit one-year high with $48.86 PT or 8.00 % above today’s $45.24 share price. It was reported on Feb, 25 by Barchart.com. The company has $1.98B MC. The valuation of NYSE:BHVN can change by $158.08M if our $48.86 PT is hit.

BHVN is touching $45.24 during the last trading session, after increased 0.52%.Biohaven Pharmaceutical Holding Company Ltd. has volume of 42,343 shares. Since February 25, 2018 BHVN has risen 94.61% and is uptrending. The stock outperformed the S&P500 by 94.61%.

On March, 5 is expected Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)’s earnings report, according to Zacks. Analysts predict 70.67 % diference or $-1.28 from the $-0.75 EPS from 2018. -16.34 % EPS growth is what analysts predict. $-1.53 EPS was announced for previous quarter.

For more Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) news brought out briefly go to: Benzinga.com, Prnewswire.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “48 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” brought out on January 30, 2019, “Biohaven Pharmaceuticals to Host Inaugural Research & Development Day on November 26, 2018 – PRNewswire” on November 20, 2018, “Biohaven licenses MPO inhibitor from AstraZeneca for the treatment of MSA – Seeking Alpha” with a publish date: September 05, 2018, “Biohaven’s trigriluzole fails to beat placebo in Phase 2/3 study in spinocerebellar ataxia; shares down 20% premarket – Seeking Alpha” and the last “Biohaven Pharma up 17% on positive data on Zydis in migraine – Seeking Alpha” with publication date: December 03, 2018.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders.The company has $1.98 billion market cap. The Company’s advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia.Currently it has negative earnings. The firm also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities.